Member Info for Hedgehog100

"Buy in cheaper... haven't you been saying that since the 40s you plum."

Thanks for showing everyone how worthless your posting is: I actually first made this a buy at 4p just over a week ago.

I actually warned people on ADVFN that ODX was overvalued at abut ten times it's current price, so I probably saved a few people some money.

But shares overshoot on both the upside and the downside, and ODX is now undervalued.

There are a lot of very sad, embittered, market abuse losers trolling this board who seriously need to get a life.

"I've quoted the only two occasions where ODX cited "legal opinion" that proved not worth a damn."

Actually TW, you haven't quoted anything.

You've made an unsubstantiated claim, just like lots of other unsubstantiated claims on this board, e.g. 'not selling anything', that are entirely false.

I haven't seen ODX quote any other legal advice they've received that has shown to be false.

So would you please stop lying, as that is market abuse.

Serious investors were very keen to invest £5M. into ODX, and they will know far more of the detail of the company than you and Captain.

"Just a ****ed off ex share holder)"

Yes, an EX shareholder.

Now deramping with sill b.s. to try to buy in a bit cheaper.

Day-to-day s.p. fluctuations often say nothing about how the business is doing.

So to call a slight dip on a few retail sales the 'last rites' is absurd.

I'm not surprised that you lost money on ODX when your investment analysis is so idiotic!

TW,

Could you give me a single example of contractural monies that were pre-paid having to be repaid because the payer decided not to proceed?

I don't need any legal advice to tell me that it's a complete nonsense.

If anything, ODX should be compensated for their aborted costs.

There's no reason to even think that the repayment request was serious: it's probably just people going through the motions for the sake of appearances, and/or perhaps using it as a bargaining counter to weigh against compensation they're worried they may have to pay to ODX.

Thanks to Arthur_Lame_Stocks on ADVFN for this useful post on Saturday:

Arthur_Lame_Stocks 26 Mar '22 - 12:48 - 2843 of 2846 0 0 0
"ODX's market cap at 4p is actually only a tad over £7m. At this price the shares are good value, the Health and Nutrition business on its own is probably worth 10p a share."

ODX could well be 'the next IDH' in my opinion: i.e. taken over at a massive premium.

And unlike some other posters here, I do actually have some past success in picking a genuinenly undervalued diagnostics company.

From ADVFN:

Hedgehog 100 22 Apr '20 - 16:59 - 142 of 263 Edit 0 0 0
"IDH is a very substantial company, which is looking massively undervalued given the current shortage of COVID-19 testing capacity. ...
Current market cap. at 225p: £64.76M. ..."
https://uk.advfn.com/cmn/fbb/thread.php3?id=26992253&from=140

17/05/2021 07:00 UK Regulatory (RNS & others) PerkinElmer Inc Offer for Immunodiagnostic Systems Holdings Plc LSE:IDH Immunodiagnostic Systems Holdings Plc
" ...The boards of PerkinElmer, Inc. ("PerkinElmer") and Immunodiagnostic Systems Holdings PLC ("IDS") are pleased to announce that they have reached agreement on the terms of a recommended all cash offer whereby the entire issued and to be issued ordinary share capital of IDS will be acquired by PerkinElmer (UK) Holdings Limited ("PerkinElmer UK") (the "Acquisition").
-- Under the terms of the Acquisition, each IDS Shareholder will be entitled to receive:
382 pence in cash per IDS Share
-- The Acquisition values the entire issued and to be issued ordinary share capital of IDS at approximately GBP110 million ($155 million), on the basis of a fully diluted share capital of 28,865,469 IDS Shares. This implies an enterprise value of IDS of approximately GBP88 million ($124 million).
-- The price of 382 pence in cash per IDS Share represents a premium of approximately:
-- 49.8 per cent. to the Closing Price of 255 pence per IDS Share on the Last Practicable Date;
-- 58.1 per cent. to the Volume Weighted Average Price per IDS Share during the one month period ended on the Last Practicable Date;
-- 68.2 per cent. to the Volume Weighted Average Price per IDS Share during the three month period ended on the Last Practicable Date; and
-- 72.5 per cent. to the Volume Weighted Average Price per IDS Share during the five year period ended on the Last Practicable Date. ..."
https://uk.advfn.com/stock-market/london/immunodiagnostic-systems-IDH/share-news/PerkinElmer-Inc-Offer-for-Immunodiagnostic-Systems/85121167

"they need to start selling something anywhere. unfortunately this is something they have never been able to do in substantial amounts."

Captain,

ODX's H1 revenue increased by 81% to £5.73m (H1 '20: £3.16m), so you are clearly posting false information when you claim they're not selling anything.

ODX's annualised revenue is £11.46M., (i.e. not allowing for H2 growth).

Pre-COVID ODX was close to breakeven on sales significantly lower than this, so at this rate of growth profitability looks perfectly within reach.

Moreover, no money has to be repaid as the legal advice is very clear, so another false statement.

ODX looks to me like a quite cracking growth company, growing like gangbusters, and at a dirt cheap price.

And that's the best way to make money in investment: to buy undervalued shares, and wait for the rerating.

29th Mar 2022 7:00 am RNS Notice of Investor Meet Company Presentation

essensys plc (AIM:ESYS), the leading global provider of mission critical software-as-a-service (SaaS) platforms and on-demand cloud services to the flexible workspace industry, is pleased to announce that the management team will provide a live presentation relating to its results for the half year ended 31 January 2022 via the Investor Meet Company platform on Friday 22nd April 2022 at 11:00am BST.

The online presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation via the "Ask a Question" function.

Investors can sign up to Investor Meet Company for free and can register to attend the presentation via the following link: https://www.investormeetcompany.com/essensys-plc/register-investor

Investors who already follow the Company on the Investor Meet Company platform will automatically be invited to attend this presentation.

https://www.lse.co.uk/rns/ESYS/notice-of-investor-meet-company-presentation-gn1khorpn6sfwmc.html

In September-October 2020 shares in Piedmont Lithium (PLL) soared about ten-fold within weeks, before and after it announced an offtake deal with Tesla.

Though they've since moved even higher.

PLL is currently AU$0.95c on the ASX, a market cap. of AU$1.56 billion.

"ENERGY SEPTEMBER 28, 20202:36 AM UPDATED 2 YEARS AGO

Australia's Piedmont signs lithium ore supply deal with Tesla, shares surge

By Reuters Staff 2 MIN READ

(Reuters) - Piedmont Lithium PLL.AX on Monday said it signed a five-year deal with Tesla Inc TSLA.O to supply high-purity lithium ore mineral to the U.S. electric carmaker, prompting an 83% surge in the Australian lithium miner's shares.

The initial five-year agreement implies that Piedmont will supply about a third of its planned 160,000-tonnes-per-year spodumene concentrate produce from its deposits in North Carolina. Both companies have an option to extend the deal for another five years. ..."

https://www.reuters.com/article/us-piedmont-lithium-deal-tesla/australias-piedmont-signs-lithium-ore-supply-deal-with-tesla-shares-surge-idINKBN26J03H

From TraderBuckie
"Check my chat history........"

O.K. Trader Buckie, here are a couple of on-topic examples:

TraderBuckie Posted in: ODX Posts: 894
Price: 99.50
Strong Buy
RE: From advfn.... 09 Feb 2021 21:13
https://www.lse.co.uk/profiles/traderbuckie/?page=24

"TraderBuckie Posted in: ODX Posts: 894
Price: 29.25
Strong Buy
RE: Colin can't do the presentation ....he's thinks he got Covid 25 Nov 2021 15:13"
https://www.lse.co.uk/profiles/traderbuckie/?page=14

So for most of last year, you were making ODX a "Strong Buy", all the way down from about £1 to c. 30p.

You then beleatedly changed your stance to "Hold".

Before finally, obsessively, urging people to sell at just a few p a share.

You'll excuse us if we decline to take your investment advice on ODX.

"The London Stock Exchange congratulates The Republic of Chile for the issuance of the world’s first sovereign Sustainability-Linked Bond

Posted: 25 March 2022 Share this page

Congratulations to The Republic of Chile for issuing the world's first sovereign sustainability-linked bond, a $2bn 4.35% note due March 2042 listed on the London Stock Exchange’s International Securities Market and Sustainable Bond Market. The milestone bond was received bids from a wide investor base diversified by both type and geography.

The bonds framework is grounded by Chile’s commitment to the Paris Agreement, featuring both a carbon emissions and renewable energy KPI. More specifically the bond is tied to the commitments that Chile emits no more than 95 metric tons of carbon dioxide and equivalent annually by 2030 and that 60% of electricity production be derived from renewable energy by 2032.

Chile issued its first green bond on the London Stock Exchange in 2019 and has since raised over £21bn equivalent in green, social, sustainability and sustainability-linked bonds on our Sustainable Bond Market. As of today, they have raised the largest amount of capital on the SBM and the only sovereign globally to have issued green, social, and sustainable bonds."

https://www.londonstockexchange.com/discover/news-and-insights/london-stock-exchange-congratulates-republic-chile

Captain,

As ODX's Health and Nutrition revenue increased by 62% to £4.17M. in H1, the existing range seems to be doing pretty well, so probably doesn't need to be broadened that much.

And the fact that you can buy a few/several £K. of ODX shares at a market cap. of £7M. is very different from buying the whole company at that price.

Try buying even 1% of the shares in issue, let along 100%, and see how much you would have to pay.

That's why takeovers of small stock market companies are typically at about double the pre-existing s.p. or even more.

How do you know no one is interested, just because it hasn't happened yet?
The s.p. hasn't been down at this level for long, and you wouldn't typically expect a takeover to happen in such a short time frame.

And the takeover of a quite similar company quite recently (i.e. IDH) is clearly very relevant here.

"Related company IDH was taken over last year at over £110M., on annual revenues of well under a third of that amount."

That should say at £110M., not over £110M.

As is usual in such cases, it was a large premium to the pre-existing market price.

And IDH and ODX were working together.

"the company have tried to place and failed...."

Captain,

Investors were more that willing to invest at 5p per share, but existing shareholders thought that that undervalued the company, so rejected the level of dilution at that s.p.

That's fair enough, because most of the funds wanted were discretionary, so there's a good argument for getting the s.p. up more first, and then raising monies for expansion in better market conditions.

In the meantime, a much smaller fundraising, even at just 5p or so, would be far more palatable than what was initially proposed.

Please note that I posted of the wrong market cap. for ODX (too high) at the weekend, so apologies for that, and thanks to Arthur_Lame_Stocks on ADVFN for correcting me. ADVFN is showing the wrong market cap. for ODX.

At a market cap of about £7M., ODX is even better value than I thought.

Related company IDH was taken over last year at over £110M., on annual revenues of well under a third of that amount.

17/05/2021 07:00 UK Regulatory (RNS & others) PerkinElmer Inc Offer for Immunodiagnostic Systems Holdings Plc LSE:IDH Immunodiagnostic Systems Holdings Plc

17/05/2021 09:21 Alliance News Immunodiagnostic Systems agrees GBP110 million bid by US's PerkinElmer LSE:IDH Immunodiagnostic Systems Holdings Plc

So my view is that ODX is clearly undervalued, and that the losses relate to the COVID fiasco, so aren't representative of the potential/likely profitability going forward.

Markets tend to look forward not back, and I think that's what people will increasingly start doing here than many are at the moment.

As regards this comment from TraderBuckie:
"Also we are about to enter a pretty grim recession (some may argue we are in it now)"

Well Trader,

What is the best sector to be in during a recession?

The consensus is that it's the health sector, as its pretty removed from the economic cycle.

Though the latest (March 2022) UK GDP aggregate forecast is for 2022 growth of 4.2%, which is far above the negative growth that constitutes a recession.
https://www.gov.uk/government/statistics/forecasts-for-the-uk-economy-march-2022

(Though do you actually know what a recession is I wonder?!)

In conclusion, T.B., you're all fluff and no substance.

Long on b.s. about corner shop sweets etc., but completely lacking in in any intelligent, fact-based analysis.

From CaptainSwag:
"i was in this share for over a year and lost a pretty fortune."
"blind hope that will one day change spots and actually sell something."

Captain,

COVID-19 has obscured the pre-COVID story here, but there's actually quite a good underlying business struggling to emerge from the COVID fiasco.

In fact, ODX's Heath & Nutrition business seems to be growing like gangbusters!

Not only a 62% H1 increase in sales, to £4.17M.

But then ODX has recently expressed confidence that this business would see significant further growth in H2, i.e. in the half ending in just a few days.

What a quite stunning performance during a pandemic!

Moreover, based ODX's total H1 revenue of £5.73M., which was a whopping 81% increase, ODX's annualised revenue is £11.46M., (i.e. not allowing for H2 growth).

At it's current market cap. of about £11.7M. at 4p, and that puts ODX on an annualised price-to-sales ratio of barely one.

Compare that to GDR: full year sales of a paltry £0.7M., a fall on the previous year, but a current market cap. of £27M. at 29.25p.

Pre-COVID ODX was close to breakeven on sales significantly lower than this, so at this rate of growth profitability looks perfectly within reach.

And then there's the takeover potential: related company IDH was taken over last year on a sales multiple far higher than ODX's and at this price ODX looks a sitting duck.

25th Nov 2021 7:00 am RNS Half-year Report

"Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, announces its unaudited interim results for the six months ended 30 September 2021.

Omega has substantial growth opportunities in the areas of Food Sensitivity, CD4 testing for the management of people living with HIV, and COVID-19 antibody and antigen testing and provides high quality in-vitro diagnostics products for use in hospitals, clinics, laboratories and healthcare practices in over 75 countries.

Financial Highlights:

· Revenue increased by 81% to £5.73m (H1 '20: £3.16m)

· Health and Nutrition sales up 62% to £4.17m (H1 '20: £2.58m)

· Global Health revenue up 170% to £1.56m (H1 '20: £0.58m) ..."

https://www.lse.co.uk/rns/ODX/half-year-report-1cp7xzpw74gnzmk.html

"I have paid dearly for my right to comment on here and I can certainly understand why 4p gives the appearance of good value...................but it isn't."

But that sort of comment is meaningless if you can't substantiate it - it's just crass nothingness.

Before COVID, the ODX s.p. was consistently in double figures, with broker valuations at multiples of that level.

Can you explain, with comparisons, your valuation of ODX?

It's interesting that as a trader, Buckie seems to have little interest in any other share to ODX: 60 of his 62 LSE posts in the last month have been on this company.

And CaptainSwag meanwhile has made 106 LSE ODX posts over the same period, though professing to have no investment interest in the company.

When a share that has fallen very heavily is experiencing this sort of obsessive deramping interest, that can sometimes be a good buy signal.

ODX recently expressed confidence that its Health and Nutrition business would see significant H2 growth, i.e. in the half ending in just a few days.

And an update on their new strategy is also due shortly.

In addition, ODX meeting the 31st. March deadline for its self-test CE Mark data would also improve confidence here.

Genedrive (GDR) had performed poorly this year until recently, declining from nearly 40p to barely 10p, but its s.p. then nearly trebled in barely a week earlier this month, fuelled by contract news.

Thanks Swissydog.

And to pick up on a point that you have made previously, re. the use of GENI's existing funds. -

From GENI's AIM Admission Document dated 16 July 2021:

"The Placing will raise approximately £17.0 million (before expenses) which is currently intended to be used, primarily, to complete the planned US launch of Cardio inCode and commercialisation."

https://investors.genincode.com/investors/admission-document

https://investors.genincode.com/docs/genincodelibraries/default-document-library/admission-document.pdf

I.e. most of the IPO monies are being saved until Cardio inCode receives FDA US marketing approval, to be used for launch and commercialisation in the US (in conjunction with their partner Eversana).